Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will progress regardless of treatment. Bilirubin <1.0 and alkaline phosphatase <2.0 x the upper limit of normal at 1 year after treatment appear to predict 10-year survival. Ursodeoxycholic acid (UDCA) is the recommended treatment for PBC, and recent studies with obeticholic acid showed promising results for UDCA non-responders. Unlike PBC, no therapy has been shown to alter the natural history of PSC. The recommended initial diagnostic test for PSC is magnetic resonance cholangiopancreatography, typically showing bile duct wall thickening, focal bile duct dilatation, and saccular dilatation of the intra- and/or extrahepatic bile ducts. Immunoglobulin 4-associated cholangitis must be excluded when considering the diagnosis of PSC, to allow for proper treatment, and monitoring of disease progression. In addition to the lack of therapy, PSC is a pre-malignant condition and close surveillance is indicated.

• Publication year

  2015

• Venue

  Clinical and Translational Gastroenterology

• Publication date

  2015-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ctg.2015.33PMID 26312413PMCID 4816277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease

  2017cited by this paper
• Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis

  2017cited by this paper
• Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.

  2015cited by this paper
• ACG Clinical Guideline: Primary Sclerosing Cholangitis

  2015cited by this paper
• A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia

  2015cited by this paper
• FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.

  2015cited by this paper
• Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

  2015influential reference
• Biliary Multifocal Chromosomal Polysomy and Cholangiocarcinoma in Primary Sclerosing Cholangitis

  2015cited by this paper
• Anti‐kelch‐like 12 and anti‐hexokinase 1: novel autoantibodies in primary biliary cirrhosis

  2015cited by this paper
• Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

  2015cited by this paper
• New Therapies for Primary Biliary Cirrhosis

  2015cited by this paper
• Current research on the treatment of primary sclerosing cholangitis.

  2015cited by this paper
• Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies

  2014cited by this paper
• Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)

  2014cited by this paper
• Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

  2014influential reference
• Primary biliary cirrhosis in 2014

  2014cited by this paper
• Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis

  2014cited by this paper
• Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis

  2014cited by this paper
• Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

  2014cited by this paper
• The clinical spectrum of IgG4-related disease.

  2014cited by this paper
• Diagnosis and classification of primary sclerosing cholangitis.

  2014influential reference
• Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis

  2014cited by this paper
• Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis.

  2014cited by this paper
• IgG4-associated cholangitis.

  2013cited by this paper
• Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

  2013cited by this paper
• Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.

  2013cited by this paper
• AUTOIMMUNE , CHOLESTATIC , AND BILIARY DISEASE Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid

  2013cited by this paper
• Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: National data from Japan

  2013cited by this paper
• Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.

  2013cited by this paper
• An update on primary sclerosing cholangitis:from pathogenesis to treatment.

  2013cited by this paper
• Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

  2013influential reference
• Tu1002 Fenofibrate Improves Alkaline Phosphatase in Primary Sclerosing Cholangitis

  2013cited by this paper
• The genetics of complex cholestatic disorders.

  2013cited by this paper
• Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

  2013cited by this paper
• Primary biliary cirrhosis: therapeutic advances.

  2013influential reference
• Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis ‐ a pilot study

  2013cited by this paper
• Increased Serum Levels of Carbohydrate Antigen 19-9 and Outcomes in Primary Sclerosing Cholangitis Patients Without Cholangiocarcinoma

  2013cited by this paper
• The great mimicker: IgG4-related disease

  2013cited by this paper
• Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19‐9 predict risk of malignancy

  2013cited by this paper
• Inflammatory disease of the bile ducts–cholangiopathies: liver biopsy challenge and clinicopathological correlation

  2012cited by this paper
• Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

  2012influential reference
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Noninvasive Elastography-Based Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cirrhosis

  2012cited by this paper
• The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis – a pilot study

  2012influential reference
• Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.

  2012cited by this paper
• Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.

  2012cited by this paper
• Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

  2012cited by this paper
• Cancer surveillance in patients with primary sclerosing cholangitis

  2011influential reference
• Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

  2011cited by this paper
• Primary Sclerosing Cholangitis Associated with Elevated ImmunoglobulinG4: Clinical Characteristics and Response to Therapy

  2011cited by this paper
• Primary biliary cirrhosis.

  2011cited by this paper
• Primary Sclerosing Cholangitis Patients With Serial Polysomy Fluorescence In Situ Hybridization Results Are at Increased Risk of Cholangiocarcinoma

  2011cited by this paper
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Incidence of Primary Sclerosing Cholangitis: a Systematic Review and Meta-Analysis

  2011cited by this paper
• Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature

  2011cited by this paper
• Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.

  2011cited by this paper
• Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis

  2010cited by this paper
• Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid

  2010cited by this paper
• Genome-wide association analysis in primary sclerosing cholangitis.

  2010cited by this paper
• Diagnosis and management of primary sclerosing cholangitis

  2010influential reference
• A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis.

  2010cited by this paper
• Bile acids: Trying to understand their chemistry and biology with the hope of helping patients

  2009cited by this paper
• EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

  2009cited by this paper
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers

  2009cited by this paper
• High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

  2009cited by this paper
• Characteristics and Long-term Prognosis of the Autoimmune Hepatitis/Primary Sclerosing Cholangitis Overlap Syndrome

  2009cited by this paper
• Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.

  2009cited by this paper
• Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008

  2009cited by this paper
• Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.

  2009cited by this paper
• A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis

  2008cited by this paper
• The natural history of small-duct primary sclerosing cholangitis.

  2008cited by this paper
• Risk of Primary Sclerosing Cholangitis and Ulcerative Colitis in irst-Degree Relatives of Patients With Primary Sclerosing Cholangitis

  2008cited by this paper
• Long-term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating Antibiotic

  2008cited by this paper
• Clinical features and management of primary sclerosing cholangitis.

  2008cited by this paper
• Clinically recurrent primary sclerosing cholangitis following liver transplantation: A time course

  2008cited by this paper
• Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.

  2008cited by this paper
• Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis

  2008cited by this paper
• High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

  2007cited by this paper
• Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis.

  2007cited by this paper
• Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

  2007cited by this paper
• Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

  2007cited by this paper
• The Burden of Large and Small Duct Primary Sclerosing Cholangitis in Adults and Children: A Population-Based Analysis

  2007cited by this paper
• Transplantation trends in primary biliary cirrhosis.

  2007cited by this paper
• Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis.

  2007cited by this paper
• Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC

  2006cited by this paper
• Primary sclerosing cholangitis: epidemiology, natural history, and prognosis.

  2006cited by this paper
• Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis

  2006cited by this paper
• Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

  2006cited by this paper
• Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial

  2005cited by this paper
• The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis

  2005cited by this paper
• Characterization, Outcome, and Prognosis in 273 Patients with Primary Sclerosing Cholangitis: A Single Center Study

  2005cited by this paper
• High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.

  2005cited by this paper
• Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?

  2004cited by this paper
• Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom.

  2004cited by this paper
• Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1.

  2004cited by this paper
• Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis

  2004cited by this paper
• Dominant Strictures in Patients with Primary Sclerosing Cholangitis

  2004cited by this paper
• Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.

  2003cited by this paper
• Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.

  2003cited by this paper
• Pharmacokinetics and pharmacodynamic action of budesonide in early‐ and late‐stage primary biliary cirrhosis

  2003cited by this paper
• Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited

  2002cited by this paper
• Small‐duct primary sclerosing cholangitis: A long‐term follow‐up study

  2002cited by this paper

• CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms

  2025cites this paper
• Evolving paradigms in primary biliary cholangitis: from molecular mechanisms to personalized therapeutics with seladelpar, elafibranor, and beyond

  2025cites this paper
• Endoscopic Balloon Dilation Versus Stent Placement in the Management of Dominant Strictures in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Tight junction proteins and biliary diseases

  2024cites this paper
• Characteristics and impact of sex in a cohort of patients with primary sclerosing cholangitis: Experience of a transplant centre in the Mediterranean basin

  2022cites this paper
• Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics

  2022cites this paper
• A comparison of balloon- versus stent-based approach for dominant strictures in primary sclerosing cholangitis: a meta-analysis

  2022influential citation
• Stent versus Balloon Dilation for the Treatment of Dominant Strictures in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis

  2021cites this paper
• Characteristics and impact of sex in a cohort of patients with primary sclerosing cholangitis: experience of a transplant center in the Mediterranean basin.

  2021cites this paper
• Prevalence and predictive value of disease specific autoantibodies over 13 years in a large cohort representative of the general population of northern Italy

  2020cites this paper
• Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis.

  2020cites this paper
• Clinical profile and outcome of primary sclerosing cholangitis: A single-centre experience from western India

  2019cites this paper
• Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.

  2019cites this paper
• Identification of clinical risk factors for histological progression of primary biliary cholangitis

  2019cites this paper
• Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?

  2019cites this paper
• Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies

  2018cites this paper
• Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study.

  2018cites this paper
• 1 Bile Acid Signaling and Cardioprotection 2

  2018cites this paper
• Abnormal Liver Enzymes

  2018cites this paper
• Endoscopic Retrograde Cholangiopancreatography and Cholangioscopy in Hepatobiliary Disease

  2017cites this paper
• Obeticholic Acid

  2017cites this paper
• Biliary Cholangitis : advances in management and treatment f the disease

  2017cites this paper
• URSODEOXYCHOLIC ACID REGULATES CASPASE-9 AND ROS PRODUCTION IN PROTECTING CARDIOMYOCYTES AGAINST HYPOXIA

  2017cites this paper
• Old and new treatments for primary biliary cholangitis

  2017cites this paper
• Current Targets for Primary Sclerosing Cholangitis.

  2017cites this paper
• Antiinflammatory and Hepatoprotective Medicinal Herbs as Potential Substitutes for Bear Bile.

  2017cites this paper
• Primary Biliary Cholangitis: advances in management and treatment of the disease.

  2017influential citation
• Endoscopic Management of Primary Sclerosing Cholangitis.

  2017cites this paper
• ADVANCES IN HEPATOLOGY Targeting the Farnesoid X Receptor in Patients With Cholestatic Liver Disease

  2016cites this paper
• Targeting the Farnesoid X Receptor in Patients With Cholestatic Liver Disease.

  2016cites this paper